Amazon is firing on multiple fronts this week, launching a direct assault on the booming weight-loss market while simultaneously deepening its push into industrial robotics. The dual announcements underscore a company intent on leveraging its vast logistics and cloud infrastructure to disrupt everything from healthcare to manufacturing.
The e-commerce giant rolled out its own GLP-1 management program on Tuesday, offering patients access to blockbuster drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Foundayo through its One Medical service. The pricing is aggressive: oral medications start at $149 per month for self-payers, while injectables begin at $299. With insurance coverage, those costs drop to a fraction. Amazon’s in-house pharmacy is already delivering prescriptions same-day to nearly 3,000 cities, with plans to expand that network to 4,500 locations by year-end.
The move sent shockwaves through the telehealth sector. Shares of Hims & Hers Health slid roughly 4% on Tuesday as analysts warned that Amazon’s Prime-powered logistics could squeeze margins for specialized players. The company’s own stock, however, remains resilient, closing at €215.20 — just shy of its 52-week high and up about 11% since January.
Robots Meet the Cloud
On the industrial side, Amazon unveiled a strategic partnership with NEURA Robotics at the Hannover Messe trade fair. The alliance centers on the “Neuraverse” platform, with AWS serving as the primary cloud provider. By linking NEURA Gym with Amazon SageMaker, the companies aim to train cognitive robots in both virtual and real-world environments. Amazon is already evaluating whether to deploy NEURA’s systems in its own logistics centers to handle complex manual tasks and boost warehouse efficiency.
Should investors sell immediately? Or is it worth buying Amazon?
The robotics push runs parallel to a broader AI offensive. AWS this week launched a suite of industry-specific AI agents built on Amazon Bedrock, developed in collaboration with Infor. Early results are striking: boat manufacturer Xpress Boats reported a 98% faster fault diagnosis in production, a 95% reduction in return processing time, and shipping costs cut in half through automated logistics planning.
Billions in the Background
These initiatives are underpinned by massive capital expenditure. Amazon is reportedly planning infrastructure investments of around $200 billion this year, much of it directed at developing proprietary chips to reduce reliance on external suppliers. The next-generation Trainium2 hardware is expected to debut in the second quarter.
The health-sector push also fits into a wider expansion wave. In mid-April, Amazon announced the $11.6 billion acquisition of Globalstar to bolster its satellite network for direct device connectivity. Separately, the company deepened its ties with AI startup Anthropic, committing up to $25 billion in exchange for the startup’s heavy spending on AWS cloud services.
Amazon shares are currently trading at €214.40, up roughly 18% over the past 30 days and hovering just below the 52-week high of €220.55. Investors will get a clearer picture on April 29, 2026, when the company reports first-quarter results. The earnings call is expected to shed light on the performance of the new healthcare division and the trajectory of AWS growth — two critical pillars of Amazon’s strategy to build a closed-loop ecosystem spanning cloud computing, custom AI chips, and physical robotics.
Ad
Amazon Stock: Buy or Sell?! New Amazon Analysis from April 22 delivers the answer:
The latest Amazon figures speak for themselves: Urgent action needed for Amazon investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 22.
Amazon: Buy or sell? Read more here...
